Background: Ischemia-reperfusion injury leads to the activation and endothelial deposition of complement. We
Ischemia-reperfusion injury leads to the activation and deposition of complement on the vascular endothelium. [1] [2] [3] [4] [5] [6] Experimental models of acute MI [3, [7] [8] [9] [10] [11] and human autopsy specimens taken from acute MI patients [12] [13] [14] [15] [16] demonstrate that complement is selectively activated in areas of infarction only. Although inhibition of complement activation or depletion of complement proteins before reperfusion has been shown to reduce tissue injury, [1, 9, 17] the mechanisms regulating complement activation at the endothelial cell surface during ischemia and reperfusion are unknown.
Complement is a cytotoxic host defense system composed of [nearly =] 20 intravascular plasma proteins subdivided into two cascade systems, the classic and alternative complement pathways. [18] Complement activation and deposition in vivo are tightly regulated by both plasma and membrane-bound complement regulators. In particular, human endothelial cells express several membrane-bound complement regulatory proteins, including MCP (CD46), DAF (CD55), and protectin (CD59). [19] DAF is a 70-kD glycoprotein that accelerates the decay of the classic and alternative C3 and C5 convertases. MCP is a 45-to 70-kD protein that binds C3b and C4b and possesses factor I-dependent cofactor activity for these two components. Whereas DAF and MCP inhibit complement activation at the level of C3, protectin is a 20-kD glycoprotein that interacts with both C8 and C9 during the assembly of C5b-9 at the membrane surface to inhibit formation of the membrane-inserted C9 homopolymer responsible for C5b-9 cytolytic activity. Despite endothelial cell-surface expression of these complement regulatory proteins, ischemia-reperfusion injury activates and deposits complement on ischemic tissues.
A recently published study using C3 and C4 knockout mice has shown an important role of the classic complement pathway in an in vivo model of hindlimb ischemia. [20] The authors suggested that hypoxia and reoxygenation of endothelial cells are responsible for complement activation and the resulting injury in this model. [20] Another study previously showed a decrease in membrane-bound complement regulatory proteins after ischemia/reperfusion injury. [15] In the present study, we investigated whether hypoxia and/or reoxygenation increases endothelial C3 deposition and decreases HUVEC-surface expression of the C3 regulatory proteins DAF and MCP in a novel in vitro model. We demonstrate that hypoxia followed by reoxygenation activates the classic complement pathway and significantly increases iC3b deposition on HUVECs. Further, we demonstrate that cell-surface expression of MCP and DAF increases after hypoxia and reoxygenation. These data suggest that endothelial deposition of C3 in the setting of ischemiareperfusion injury is augmented by reoxygenation and is not due to a loss of surface expression of the C3 complement regulatory proteins MCP and DAF.
Methods

Cell Culture
HUVECs were obtained as previously described. [21, 22] Briefly, HUVECs were harvested by use of 0.1% collagenase (Worthington Biochemical Corp) and suspended in medium 199 containing 20% heat-inactivated BCS (Gibco Life Technologies Inc). The cells were initially seeded in either 75-cm 2 flasks or 100-mm Petri dishes (Corning Costar) and incubated at 37 [degree sign] Celsius in 95% air/5% CO 2 . When confluent, the endothelial cells were passaged with 0.5% trypsin-EDTA. Endothelial cell purity was assessed by a phase-microscopic "cobblestone appearance" and uptake of fluorescent acetylated LDL. All experiments were conducted on HUVECs during passages 1 through 3.
Cell-Surface ELISA Experiments
A C3-specific cell-surface ELISA was developed with a peroxidase-conjugated polyclonal goat anti-human C3
antibody (Cappel). HUVECs were grown to confluence on 0.1% gelatinized 96-well plastic plates (Corning Costar). The plates were then divided into the following groups: (1) normoxia (control), (2) antibody was added (ie, no HS). Background optical density was subtracted from all groups. All ELISA experiments were performed two or three times with six wells used per experimental group (n = 12 to 18).
Flow Cytometry
HUVECs were grown to confluence in 60-mm Petri dishes coated with gelatin. Cell-surface C3 deposition was measured by flow cytometry in normoxic HUVECs and HUVECs subjected to 24 hours of hypoxia followed by 3 hours of reoxygenation in the presence of 30% HS. After the cells were washed and fixed in 1% paraformaldehyde, they were Washed immunoprecipitates were boiled in nonreducing sample buffer (2.5% SDS, 0.38 mol/L Tris, pH 6.8, 20%
glycerol, and 0.1% bromphenol blue), separated by SDS-PAGE (10% linear gel) under nonreducing conditions, and transferred to nitrocellulose by standard protocols. Biotiny-lated proteins were labeled with streptavidin-peroxidase (Pierce) and visualized by enhanced chemiluminescence.
Statistical Analysis
Ovid: Reoxygenation of Hypoxic Human Umbilical Vein Endothelial Cell... http://ovidsp.tx.ovid.com.ezp-prod1.hul.harvard.edu/sp-3.8.0b/ovidweb.cgi 3 of 14 2/19/2013 11:45 AM All data are expressed as mean +/-SEM. Data analyses were performed with Sigma Stat (Jandel Scientific).
Endothelial C3 deposition and HUVEC-surface expression of MCP and DAF in normoxic versus hypoxic HUVECs (ELISA) was analyzed by two-way ANOVA. All pairwise multiple comparisons were made with the Student-Newman-Keuls test.
The reduced Western blots were scanned and then analyzed by a nonpaired Student's t test. Optical density for all ELISA data are presented with background subtracted.
Results
Effect of Hypoxia Versus Hypoxia and Reoxygenation
Cell-surface C3 deposition was measured by ELISA in normoxic HUVECs and HUVECs subjected to either hypoxia alone or hypoxia followed by reoxygenation. C3 deposition on HUVECs subjected to 12 or 24 hours of hypoxia followed by 3 hours of reoxygenation was significantly greater (P < .05) than normoxic HUVECs (with or without reoxygenation)
or HUVECs subjected to only 12 or 24 hours of hypoxia ( Figure 1 ). C3 deposition on HUVECs subjected to only 12 or 24
hours of hypoxia did not differ significantly from normoxic HUVECs (with or without reoxygenation). C3 deposition after hypoxia and reoxygenation was also confirmed by flow cytometry (Figure 2 ). MFI in HUVECs subjected to 24
hours of hypoxia was greater than that in normoxic HUVECs after 3 hours of incubation in 30% HS. C3 deposition (ie, MFI) was augmented in HUVECs subjected to 24 hours of hypoxia followed by reoxygenation (3 hours) in 30% HS. MFI in HUVECs not exposed to HS and subjected to normoxia, hypoxia, or hypoxia and reoxygenation did not differ. Figure 1 . Cell-surface deposition of C3 on HUVECs. C3 deposition was studied by ELISA in HUVECs subjected to 12 or 24 hours of hypoxia followed by 3 hours of reoxygenation with a polyclonal goat anti-human C3 antibody. C3 deposition was significantly increased in HUVECs subjected to 12 or 24 hours of hypoxia followed by 3 hours of reoxygenation. n = 12; error bars indicate SEM; *P < .05 compared with respective hypoxic-only group and with normoxic HUVECs with or without reoxygenation. 
Inhibition of the Classic Complement Pathway
To investigate whether C3 deposition involved activation of the classic complement pathway, human serum containing MgCl 2 /EGTA was added to inhibit the classic complement pathway. C3 deposition on HUVECs subjected to 24 hours of hypoxia followed by 3 hours of reoxygenation was significantly greater (P < .05) than normoxic (ie, control) 
Inhibition of the Classic and Alternative Complement Pathways With Complement-Depleted Sera
To further investigate the mechanism of C3 deposition, HUVECs were reoxygenated in the presence of C2-depleted HS or factor B-depleted HS to inhibit the classic and alternative complement pathway activity, respectively. C3 deposition on HUVECs subjected to 24 hours of hypoxia followed by 3 hours of reoxygenation in the presence of HS or factor B-depleted HS was significantly greater (P < .05) than normoxic HUVECs (Figure 3 ). However, C3 deposition on HUVECs reoxygenated in the presence of C2-depleted HS did not differ significantly from normoxic HUVECs. When C2 was added back to the C2-depleted HS, C3 deposition on HUVECs after 24 hours of hypoxia and 3 hours of reoxygenation was significantly greater (P < .05) than normoxic HUVECs and did not differ significantly from
HUVECs receiving HS. These data demonstrate that C3 deposition is specific and not a result of nonspecific C3 binding.
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Discussion
We have shown that human endothelial cells after hypoxia induced complement activation demonstrated by increased iC3b deposition. C3 deposition on hypoxic HUVECs was augmented by reoxygenation. Complement activation in this model is largely dependent on activation of the classic complement pathway. We also demonstrate that HUVECsurface expression of the C3 regulators MCP and DAF increases after hypoxia and reoxygenation. We conclude that hypoxia and reoxygenation of human endothelial cells activates the classic complement pathway despite an increase in surface expression of complement regulatory proteins.
Complement Activation During Ischemia/Reperfusion
Since complement concentrations are highest in the plasma, one might expect that complement activation first takes place intravascularly on the endothelium and then proceeds extravascularly during ischemia/reperfusion.
Weisman and colleagues [9] have shown that C5b-9 is deposited only on the coronary endothelium during the early phase of reperfusion. Buerke and colleagues [17] recently demonstrated that C1q is deposited on the coronary endothelium after myocardial ischemia and reperfusion in cats. A recent in vivo study by Weiser and colleagues [20] suggested that ischemia and reperfusion of endothelial cells may activate complement by expression of neoantigens at the endothelial cell surface. Thus, previous studies have demonstrated that complement is deposited on the vascular endothelium. Our study demonstrates not only that complement is deposited on endothelial cells but also that hypoxic/reoxygenated endothelial cells become complement activators.
Complement is known to be activated during ischemia and reperfusion. [1] [2] [3] [4] [5] [6] However, the mechanisms regulating complement activation during ischemia/reperfusion are not understood. It is possible that the complement regulatory proteins MCP, DAF, and protectin are shed from the endothelial surface or become inactivated during reperfusion. This is particularly important because DAF and protectin are glycosylphosphatidyl-inositol-linked proteins, and phospholipases are known to be activated during ischemia and reperfusion. [25] We demonstrate that hypoxia and reoxygenation significantly increase HUVEC-surface expression of DAF and MCP in the present study. Furthermore, we recently identified the presence of another complement regulatory protein on HUVECs, complement receptor one (CR1; CD35). [26] HUVEC-surface expression of CR1 is also increased after hypoxia. [26] Thus, complement activation and C3 deposition occur in this model despite increased surface expression of these C3 complement regulatory proteins. It should be noted that although MCP, DAF, and protectin are known to be present on human endothelial cells, [25, 27] only protectin is present on cardiomyocytes. [16] Therefore, myocytes may be even more vulnerable to complement-mediated injury than the endothelium.
We have demonstrated that reoxygenation augments complement deposition in this model. Interestingly, studies
of acute MI lesions demonstrate increased myocardial deposition of complement in reperfused MI lesions compared with nonreperfused MI lesions. [10] Oxygen-derived free radicals have been shown to activate the terminal complement cascade by converting C5 to a functionally active C5b-like metabolite. [28] In addition, oxygen-derived free radicals have been shown to mediate endothelial cell damage by complement-stimulated granulocytes. [29, 30] However, direct activation of C3 or the classic complement pathway by oxygen-derived free radicals has not been demonstrated. Because the increase in C3 deposition on HUVECs is augmented by reoxygenation, we are currently investigating whether the formation of oxygen-derived free radicals during reoxygenation activates complement in this model. The importance of complement activation after reoxygenation of hypoxic HUVECs is highlighted by experimental studies in which inhibition of complement activation, complement depletion, or functional inhibition of C5a during reperfusion significantly decreases infarct size. [8, 9, 31, 32] However, the initiating step and site of complement activation in vivo during ischemia and reperfusion is not known. Myocardial deposition of the classic complement pathway components C1q, C4, and C3 has been demonstrated, whereas myocardial deposition of properdin (a specific marker for alternative complement pathway activation) was not observed. [8, 16, 17] Similarly, Rossen and colleagues [33] demonstrated that mitochondrial membrane and cardiolipin-containing fragments released from ischemic tissues can bind Clq and activate the classic complement pathway. Thus, complement can be activated by myocardial fragments and deposited within the myocardium. The mechanism of complement activation in our model is presently under investigation.
Characterization of C3 Deposition
Our data demonstrate that C3 is deposited on endothelium after hypoxia and reoxygenation. C3, the most abundant complement component, is composed of an alpha-chain (with an internal disulfide bond) linked to a beta-chain by a disulfide bond. In the presence of the alternative or classic C3 convertase, C3 is cleaved into the anaphylatoxin C3a and C3b. The C3 activation step exposes a thioester bond in the C3d region of the C3 alpha-chain.
The thioester bond is very unstable and allows C3b to attach covalently to cell membranes. This is an important step, because C3b deposition to a cell surface allows initiation of the terminal complement complex, C5b-9, and can serve to amplify the alternative complement pathway. In the presence of the fluid-phase factor I and one of several cofactors (MCP, CR1, CR2, factor H, or C4bp), C3b is degraded to iC3b. iC3b is further degraded to the fluid-phase complement component C3c and the membrane-bound C3dg molecule.
Under reducing conditions, iC3b liberates three separate peptides: a beta-chain (75.5 kD), an alpha 2 -chain (63 kD), and another 39.5-kD peptide from the alpha-chain. We did not observe a "C3" alpha-chain in the reduced cell lysates or from purified iC3b antigen on Western blots using the polyclonal anti-human C3 antibody (Figure 4(A) ).
These data suggest that the C3 species present on the HUVECs is not a result of nonspecific C3 binding or C3b but rather another C3 species. We did observe a significant increase in the beta-chain density in hypoxic HUVEC lysates compared with normoxic lysates. To identify the C3 species present on the HUVECs, we used a polyclonal anti-C3d
antibody. The C3d antibody identified a band, alpha 2 , in normoxic and hypoxic/reoxygenated lysates under reducing conditions with a molecular weight equivalent to the reduced iC3b alpha-chain (Figure 4(B) , left). The alpha 2 band density was significantly greater in the hypoxic/reoxygenated lysates than with normoxia. Dual probing of a Western blot with the polyclonal anti-C3 and anti-C3d antibodies allowed us to identify the iC3b alpha-chain (alpha 2 ) and the beta-chain on the same Western blot (Figure 4 (B), right). We further documented that the C3 species on the HUVECs was iC3b by additional flow cytometry experiments using a monoclonal antibody to a neoepitope on iC3b. These flow cytometry data confirmed our Western blot data demonstrating significantly enhanced iC3b under hypoxic conditions compared with normoxia. Reoxygenation of the hypoxic HUVECs augmented iC3b deposition. These data demonstrate that (1) the polyclonal antibody to human C3 does not recognize the iC3b alpha-chain under reduced conditions and (2) iC3b but not C3 or C3b deposition is significantly increased on hypoxic/reoxygenated HUVECs.
Complement activation leads to the production of several important biologically active components, namely, C5a, iC3b, and C5b-9. Endothelial deposition of iC3b has been shown to be a potent stimulus for increased adhesion of neutrophils. [34] [35] [36] Similarly, C5b-9 and C5a induce endothelial expression of the neutrophil adhesion molecule P-selectin. [37, 38] Our study demonstrates that iC3b is the C3 complement component deposited in this model. Thus, activation of complement may initiate the recruitment and endothelial attachment of neutrophils in ischemic/reperfused tissues. Future studies observing the increased adherence of neutrophils in this model are warranted.
Limitations to the Model/Study
We recognize that this study is an in vitro model using hypoxia/reoxygenation. Hypoxia/reoxygenation is only one studies were performed on HUVECs during passages 1 through 3, and these cells did express complement regulatory molecules. Future studies using arterial endothelial cells are planned. Third, although DAF and MCP are physically present on HUVECs and are increased by hypoxia and reoxygenation, the mere presence of these complement regulators does not necessarily denote functional activity. However, functional data for these complement regulators would be difficult to obtain because of the overlapping functional properties and the lack of sufficient quantities of functionally inhibitory Fab fragments.
In summary, we conclude that (1) hypoxia leads to complement activation and deposition of C3 on HUVECs (2) reoxygenation of hypoxic HUVECs augments C3 deposition, (3) bound C3 was characterized as iC3b by Western analysis and flow cytometry, (4) C3 deposition after hypoxia and reoxygenation is largely mediated by the classic complement pathway, and (5) HUVEC-surface expression of DAF and MCP increases after hypoxia and reoxygenation. These data demonstrate that hypoxia and/or reoxygenation of human endothelial cells activates the classic complement pathway despite increased expression of C3 regulatory proteins. 
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